University of Rhode Island

DigitalCommons@URI
Cell and Molecular Biology Faculty Publications

Cell and Molecular Biology

1-2021

Temporally Integrated Single Cell RNA Sequencing Analysis of
PBMC from Experimental and Natural Primary Human DENV-1
Infections
Adam T. Waickman
Heather Friberg
Gregory D. Gromowski
Wiriya Rutvisuttinunt
Tao Li

See next page for additional authors

Follow this and additional works at: https://digitalcommons.uri.edu/cmb_facpubs

Creative Commons License
/">
This work is licensed under a Creative Commons Public Domain Dedication 1.0 License.
Citation/Publisher Attribution
Waickman AT, Friberg H, Gromowski GD, Rutvisuttinunt W, Li T, Siegfried H, et al. (2021) Temporally
integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human
DENV-1 infections. PLoS Pathog 17(1): e1009240. https://doi.org/10.1371/journal.ppat.1009240

This Article is brought to you for free and open access by the Cell and Molecular Biology at DigitalCommons@URI.
It has been accepted for inclusion in Cell and Molecular Biology Faculty Publications by an authorized administrator
of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

Authors
Adam T. Waickman, Heather Friberg, Gregory D. Gromowski, Wiriya Rutvisuttinunt, Tao Li, Hayden
Siegfried, Kaitlin Victor, Michael K. McCracken, Stefan Fernandez, Anon Srikiatkhachorn, Damon Ellison,
Richard G. Jarman, Stephen J. Thomas, Alan L. Rothman, Timothy Endy, and Jeffrey R. Currier

This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/cmb_facpubs/148

PLOS PATHOGENS
RESEARCH ARTICLE

Temporally integrated single cell RNA
sequencing analysis of PBMC from
experimental and natural primary human
DENV-1 infections

a1111111111
a1111111111
a1111111111
a1111111111
a1111111111

OPEN ACCESS
Citation: Waickman AT, Friberg H, Gromowski GD,
Rutvisuttinunt W, Li T, Siegfried H, et al. (2021)
Temporally integrated single cell RNA sequencing
analysis of PBMC from experimental and natural
primary human DENV-1 infections. PLoS Pathog
17(1): e1009240. https://doi.org/10.1371/journal.
ppat.1009240
Editor: Daniela Weiskopf, UNITED STATES
Received: August 26, 2020
Accepted: December 15, 2020
Published: January 29, 2021
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.ppat.1009240
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced,
distributed, transmitted, modified, built upon, or
otherwise used by anyone for any lawful purpose.
The work is made available under the Creative
Commons CC0 public domain dedication.

Adam T. Waickman ID1,2,3*, Heather Friberg ID1, Gregory D. Gromowski1,
Wiriya Rutvisuttinunt1, Tao Li1, Hayden Siegfried ID1, Kaitlin Victor ID1, Michael
K. McCracken1, Stefan Fernandez4, Anon Srikiatkhachorn5,6, Damon Ellison1, Richard
G. Jarman ID1, Stephen J. Thomas2, Alan L. Rothman ID5, Timothy Endy ID3, Jeffrey
R. Currier1
1 Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of
America, 2 Institute for Global Health and Translational Sciences, State University of New York Upstate
Medical University, Syracuse, New York, United States of America, 3 Department of Microbiology and
Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States of
America, 4 Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok,
Thailand, 5 Department of Cell and Molecular Biology, Institute for Immunology and Informatics, University of
Rhode Island, Providence, Rhode Island, United States of America, 6 Faculty of Medicine, King Mongkut’s
Institute of Technology Ladkrabang, Bangkok, Thailand
* waickmaa@upstate.edu

Abstract
Dengue human infection studies present an opportunity to address many longstanding
questions in the field of flavivirus biology. However, limited data are available on how the
immunological and transcriptional response elicited by an attenuated challenge virus compares to that associated with a wild-type DENV infection. To determine the kinetic transcriptional signature associated with experimental primary DENV-1 infection and to assess how
closely this profile correlates with the transcriptional signature accompanying natural primary DENV-1 infection, we utilized scRNAseq to analyze PBMC from individuals enrolled in
a DENV-1 human challenge study and from individuals experiencing a natural primary
DENV-1 infection. While both experimental and natural primary DENV-1 infection resulted
in overlapping patterns of inflammatory gene upregulation, natural primary DENV-1 infection
was accompanied with a more pronounced suppression in gene products associated with
protein translation and mitochondrial function, principally in monocytes. This suggests that
the immune response elicited by experimental and natural primary DENV infection are similar, but that natural primary DENV-1 infection has a more pronounced impact on basic cellular processes to induce a multi-layered anti-viral state.
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article and its Supplementary Information files.
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Transcriptional analysis of experimental and natural primary DENV-1 infection

Author summary
Dengue Human Challenge Models allow for the analysis of host/virus interactions under
highly controlled experimental conditions. However, it is unclear how close the immune
response generated by an attenuated challenge virus compares to that generated by a naturally acquired DENV infection. In this study, we utilized single cell RNA sequencing to
assess the immune response generated by both experimental and natural primary DENV1 infections. This analysis suggests that the immune response elicited by experiential and
natural primary DENV-1 infections are similar, but that natural DENV-1 infection has a
more pronounced impact on basic cellular processes to induce a multi-layered anti-viral
state.

Introduction
Dengue is one of the most widespread vector-borne viral diseases in the world. The causative
agent–dengue virus (DENV)–is a positive-stranded RNA virus maintained in an anthroponotic cycle between the Aedes aegypti mosquito and humans [1]. Consisting of four co-circulating
but immunologically and genetically discrete serotypes (DENV-1, -2, -3, and -4), DENV is
thought to infect up to 300 million individuals yearly [2,3]. Although the majority of DENV
infections are subclinical, as many as 100 million infections every year result in symptomatic
dengue fever. In its most severe manifestation, dengue fever can progress to dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) [4–7]. While the pathogenesis of severe dengue is complex and may involve some degree of genetic predisposition, severe symptoms are
more likely to occur in individuals previously infected with a heterologous viral serotype compared to individuals without any preexisting DENV immunity [8,9]. Despite decades of study,
the precise mechanisms underpinning this unique epidemiological feature of DENV infection
remain unresolved and continues to impede the development of an effective DENV vaccine.
In addition to the unclear role of preexisting immunity and other host/environmental factors on the immunopathogenesis of DENV infection, the fundamental immunological and
molecular signatures associated with early DENV infection remain mostly unresolved. This is
partially attributable to the endemic nature of DENV–resulting in frequent and unpredictable
exposures in susceptible individuals -as well as the wide variation in the kinetics of asymptomatic incubation/infection prior to any symptomatic manifestation of infection [10]. Resolving
the early unique immunological and molecular signatures specific to DENV infection would
aid in the development of rapid diagnostic tools, as well as provide insight into the basic pathophysiology of infection and disease.
DENV human infection models (DHIMs) offer a unique opportunity to formally address
many of the outstanding questions in the field of DENV biology. By exposing pre-screened
individuals to DENV in a controlled setting, it is possible to closely monitor the immunological response elicited by infection prior to the onset of any traditional clinical symptoms. In
addition to providing a platform to answer many fundamental questions of flavivirus biology,
DHIMs are a powerful tool to systematically develop and down-select candidate vaccine platforms or therapeutic agents in a controlled setting before expanding to large-scale efficacy trials. Indeed, Kirkpatrick and colleagues have demonstrated the utility of this approach by
utilizing an attenuated DENV-2 challenge virus to test the efficacy of the TV003 DENV vaccine product prior to the initiation of larger efficacy trials [11].
While the earliest DHIM studies performed in the 1930s utilized unattenuated wild-type
DENV strains, all current DHIM studies utilize highly characterized and attenuated viral
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strains. Viral attenuation is critical to ensure an acceptable safety profile, but it leaves open the
possibility that the causative mutations may significantly alter the immunological response
elicited by infection, thereby reducing the utility of the model. Limited data are available on
how closely these experimental primary DENV infections mimic the immunological subtleties
and complexities of natural primary DENV infection. The majority of DHIMs appear to recapitulate the basic clinical features associated with mild natural primary DENV infection,
including rash, myalgia, headache, and fever, as well as the crude virologic/serologic features
of infection such as peripheral viremia/RNAemia and DENV-specific seroconversion [12,13].
However, no study to date has attempted to directly compare/contrast the molecular signatures associated with either natural or experimental primary DENV infection with any degree
of cellular and/or temporal resolution. Understanding how closely an experimental primary
DENV infection mimics the molecular subtleties of a wild-type DENV infection would inform
decisions on how best to utilize the tool for product down-selection, as well as provide insight
into the basic molecular response elicited by primary DENV infection with an unparalleled
degree of temporal resolution.
To close this significant knowledge gap, we utilized high-throughput single-cell RNA
sequencing (scRNAseq) technology to assess the longitudinal transcriptional profile associated
with both experimental and natural primary DENV-1 infection with single-cell resolution.
This study utilized samples collected as part WRAIR/SUNY phase one open label DENV-1
human challenge study performed in Syracuse, NY [12], as well as samples collected from children enrolled in a hospital-based acute dengue study in Bangkok, Thailand [14]. Unfractionated PBMC from 8 time points (days 0, 2, 4, 6, 8, 10, 14/15 and 28) from 3 individuals
enrolled in the experimental primary DENV-1 infection study were analyzed, as well as 3 time
points (acute 1, acute 2, day 180) from two individuals experiencing a natural primary DENV1 infection. This temporally integrated analysis resulted in the capture of 171,208 cells, which
upon examination collapsed into 22 statistically distinct populations corresponding to all
major anticipated leukocyte subsets. While all annotated cell populations demonstrated significant and consistent perturbations in their transcriptional profile in response to either natural
or experimental primary DENV-1 infection, conventional monocytes respond most robustly
to infection across all subjects and study groups from an unbiased transcriptional perspective.
Using these data, conserved Differentially Expressed Genes (cDEGs) induced or suppressed by
natural or experimental primary DENV-1 were identified, and the overlap between the two
arms of the study assessed. The infection-induced cDEGs associated with experimental primary DENV-1 infection were found to reflect a subset within the larger gene set associated
with natural primary DENV-1 infection, primarily corresponding to gene products associated
with a cellular response to systemic inflammation and interferon (IFN) production. In contrast, the number of infection-suppressed cDEGs was higher in cells obtained following natural
primary DENV-1 infection than in cells obtained following experimental primary DENV-1
infection. Infection-suppressed cDEGs primarily corresponded to gene products associated
with protein translation/elongation and mitochondrial function, two cellular processes known
to be suppressed by prolonged IFN signaling. These results are consistent with the concept
that the immune response elicited by an experimental primary DENV-1 infection represents a
tempered version of that generated in response to a natural primary DENV-1 infection, and
that the more pronounced inflammation associated with natural primary DENV-1 infection
has a correspondingly more pronounced impact on basic cellular processes to induce a multilayered/systemic anti-viral state. These data provide insight into the molecular level response
to primary DENV-1 infection, and how viral pathogenesis correlates with immune activation
and cellular pathophysiology.
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Results
Subject selection and characterization
The primary objective of this study was to determine the kinetic transcriptional signature associated with experimental primary DENV-1 infection and to determine how closely this profile
correlates with the transcriptional signature accompanying natural primary DENV-1 infection. To this end, three subjects from the SUNY/WRAIR DENV-1 DHIM study were selected
for analysis based on their representative viremia and seroconversion kinetics relative to the
SUNY/WRAIR DHIM-1 study as a whole (Fig 1A) [12]. This human challenge study utilized
the 45AZ5 DENV-1 virus strain, which is an under-attenuated DENV-1 vaccine candidate
generated by serial passage of the parental Nauru/West Pac/1974 DENV-1 isolate through diploid fetal rhesus lung cell line (FRhL) in the presence of 5-azacytidine [15,16]. This in vitro
attenuation process resulted in the introduction of 25 nucleotide and 10 amino acid substitution in the attenuated 45AZ5 strain relative to the parental Nauru/West Pac/1974 DENV-1 isolate, with substitutions observed in the E, NS3, NS4a, and NS5 genomic regions of the virus
[15].
All subjects included in this study received 3.25 x 103 PFU of the 45AZ5 DENV-1 challenge
virus strain following extensive pre-screening to ensure an absence of preexisting DENV
immunity. All three subjects exhibited significant DENV-1 RNAema between 5 and 15 days
post-challenge and demonstrated classic staggered IgM/IgG seroconversion between study
days 13 and 16 (Figs 1A and S1). PBMC from a total of 8 time points per subject were selected
for this study, corresponding to study days 0, 2, 4, 6, 8, 10, 14/15, and 28. In addition, PBMC
from two children experiencing serologically-confirmed natural primary DENV-1 infections
were selected for analysis (Figs 1B and S1 and S1 Table). A total of 3 time points per subject
were analyzed: two sequential samples collected during the acute (febrile) phase of infection,
and a reference sample collected 6 months post-defervescence. For both the experimental and
natural primary DENV-1 infection subjects, each sample was analyzed in parallel by scRNAseq
and by flow cytometry (S1, S2 and S3 Figs).

Fig 1. Subject characterization and experimental overview. A) Kinetics of RNAemia and DENV IgM/IgG
seroconversion in experimental primary DENV-1 infection subjects. Serum IgM/IgG titers calculated as highest serum
dilution providing a 2X signal over background. B) Kinetics of IgM/IgG seroconversion and duration of fever in natural
primary DENV-1 infection subjects analyzed in this study. DENV-reactive serum IgM/IgG levels shown as EIA units.
https://doi.org/10.1371/journal.ppat.1009240.g001
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Leukocyte population identification and quantification
In order to assess the transcriptional signature associated with experimental and natural primary DENV-1 infection, high-throughput scRNAseq analysis was performed using the 10x
Genomics 5’ capture gene expression platform. Samples were sequenced to achieve a mean
depth of 108,000 reads per cell, with an average of 5,707 cells captured per library (S2 Table).
This final dataset contains a total of 171,208 high quality cells and 22 statistically distinct populations corresponding to all major anticipated leukocyte subsets (Fig 2A and 2B and S3 and
S4 Tables). With the exception of neutrophils, all annotated populations were consistently
observed in all experimental and natural primary DENV-1 infection samples included in this
analysis (Fig 2C and S3 and S4 Tables). The relative distribution of all major leukocyte populations was consistent within each subject across all analyzed time point, with the notable
exception of activated T cells and plasmablast phenotype B cells, both of which expanded in
response to infection in the experimental primary DENV-1 infection subjects on study days
14/15 (Figs 2D, S4, S5 and S6). No T cell or B cell activation/expansion was observed in the
natural primary DENV-1 infection samples, constant with the time points analyzed [17]. To
validate the population annotations as defined by scRNAseq, conventional flow cytometry was
performed in parallel on the same samples and the frequencies of major leukocyte populations
assessed (S2 and S3 Figs). The frequencies of all major leukocyte populations captured by
either scRNAseq or flow cytometry exhibited a high degree of correlation across all time points
in the experimental primary DENV-1 infection sample set (S7 Fig). No cell-associated DENV1 RNA was observed in any sample at any time point following either experimental or natural
primary DENV-1 infection.

Identification of conserved experimental primary DENV-1 infection
associated gene signatures
To determine the kinetics and composition of the subject/population-specific transcriptional
response to experimental primary DENV-1 infection, we performed differentially expressed
gene (DEG) analysis across all experimental primary DENV-1 infection samples. For this analysis, each annotated cell population on post-challenge study days was compared to the same
population from the subject’s baseline sample (study day 0) using a Wilcoxon Log Rank test
with a Bonferroni correction for multiple comparisons. Only genes with corrected p value
of < 0.05 also exhibiting a >0.5 fold change in expression were considered significant.
Although some modest and inconsistent transcriptional changes were observed on study day 6
and 8, it was at study day 10 that a consistent and robust transcriptional response to experimental primary DENV-1 infection was observed across all subjects (Fig 3A). The cellular populations exhibiting the most dramatic response to experimental primary DENV-1 infection
were conventional and CD16hi monocytes, with both populations containing > 100 DEGs on
study day 10.
To better define the conserved “core” transcriptional signature associated with experimental primary DENV-1 infection, we reduced our differential transcriptional analysis to only
contain genes that were differently expressed from baseline in all three experimental primary
DENV-1 infection subjects at the indicated time point (Fig 3B and S5 Table). These conserved
DEGs (cDEGs) were additionally separated into those induced by infection, and those suppressed by infection. This modified analysis again demonstrated that both conventional and
CD16hi monocytes exhibited the most robust conserved transcriptional response to experimental primary DENV-1 infection, followed in magnitude by NK/NKT cells, and CD8+ Effector Memory (E/M) cells (Fig 3B and S5 Table). The majority of the annotated cDEGs were
upregulated by experimental primary DENV-1 infection, with only a minor population of
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Fig 2. Annotation and quantification of major leukocyte populations following experimental or natural primary DENV-1 infection. A)
Integrated UMAP projection of scRNAseq data from all annotated leukocyte populations derived from all experimental primary DENV-1
infection subjects (n = 3, 8 time points per subject) and natural primary DENV-1 infection subjects (n = 2, 3 time points per subject). B)
Expression of key linage defining gene products across all annotated leukocyte populations captured in this analysis. C) Integrated UMAP
projection of all annotated leukocyte populations split by subject, including all time points. D) Relative population abundance in all subjects split
by time point.
https://doi.org/10.1371/journal.ppat.1009240.g002
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Fig 3. Temporal and transcriptional characterization of experimental primary DENV-1 infection and identification of conserved gene
signatures. A) Quantification of differential gene expression across all major leukocyte populations following experimental primary DENV-1
infection. Subject- and population-specific differentially expressed genes (DEGs) were defined by a Wilcoxon rank-sum test with a
Bonferroni correction relative to study day 0 for each subject. B) Population-restricted frequency and temporal dynamics of cDEGs across all
experimental primary DENV-1 infection subjects. Conserved DEGs defined as DEGs observed in all three subjects at the same time point
relative to baseline. C) Expression of select upregulated cDEGs from study day 10 within the indicated cell populations across all study time
points. D) Expression of select suppressed cDEGs from study day 10 within the indicated cell populations across all study time points.
https://doi.org/10.1371/journal.ppat.1009240.g003

cDEGs consistently suppressed in response to experimental primary DENV-1 infection (Fig
3B and S5 Table). The genes that were most consistently and significantly upregulated following experimental primary DENV-1 infection primarily corresponded to interferon-induced
gene products (e.g. IFITM1, IFI6, ISG15, and MX1) and other genes associated with acute
inflammation (e.g. TRIM22 and LY6E) (S5 Table). The expression of these gene products consistently peaked on study days 10–14, and trended towards baseline by study day 28 (Fig 3C
and S5 Table). The few cDEGs that were repressed in response to experimental primary
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DENV-1 infection primarily corresponded to ribosomal protein subunits (e.g. RPL4, RPL5
and RPL6) translation elongation products (e.g. EEF2, EIF3L and EIF4B) mitochondrial associated gene products (e.g. MT-CYB and MT-ND4) (Fig 3D and S5 Table). This transcriptional profile is consistent with canonical IFN-associated suppression of protein translation
and mitochondrial biogenesis and highlights a key mechanistic response to acute viral infection [18,19]. These conserved transcriptional responses to experimental primary DENV-1
infection not only reflect the acute cytokine-driven response to inflammation and infection
but also capture the physiological response to inflammation and the induction of a distributed
classic anti-viral cellular state in conventional and CD16hi monocytes.

Identification of conserved natural primary DENV infection gene
signatures
Having defined the kinetics and core conserved transcriptional profile associated with experimental primary DENV-1 infection, we performed the same analysis on the cells from individuals experiencing a natural primary DENV-1 infection. For this analysis, each annotated cell
population from a given subject’s acute infection sample set (acute #1 and acute #2) was compared to the same population from the subject’s 6-month reference sample (Fig 4A). As was
observed following experimental primary DENV-1 infection, the cellular populations exhibiting the most dramatic response to natural primary DENV-1 infection were conventional and
CD16hi monocytes, with both populations containing > 300 DEGs in both acute time points
in both subjects. However, the number of population-specific DEGs observed in response to
natural primary DENV-1 infection was several fold higher than the response observed in the
same population following experimental primary DENV-1 infection (S8 Fig).
To reduce the complexity of the data, we again endeavored to define a core set of populationspecific cDEGs within the natural primary DENV-1 infection dataset. As the samples obtained
from natural primary DENV-1 infection were collected on consecutive days and the exact timing
post-infection is unknown, cDEGs for these samples were defined as those gene products differentially expressed in all acute infection time points relative to their respective reference sample
(the intersection of the acute timepoint DEGs). Conventional monocytes, memory CD4+ T cells,
and CD8+ EM cells exhibited the largest number of upregulated cDEG across all annotated cell
populations, with the majority of the conserved upregulated DEGs corresponding to classic interferon-induced gene products (e.g. IFIT1, IFI44L, and ISG20) and other genes associated with
acute inflammation (e.g. TRIM22 and LY6E) (Fig 4B and 4C and S6 Table). In contrast to the
modest number of cDEGs suppressed in response to experimental primary DENV-1 infection, a
significant fraction of the cDEGs identified in natural primary DENV-1 infection were suppressed relative to baseline (Fig 4B). However, similarly to those suppressed conserved DEGs
identified following experimental primary DENV-1 infection, the suppressed cDEGs identified
following natural primary DENV-1 infection primarily corresponded to ribosomal protein subunits (e.g. RPL4, RPL5, and RPL6), translation elongation products (e.g. EEF2, EIF3L, and
EIF4B) and mitochondrial associated gene products (e.g. MT-CYB, and MT-ND4) (Fig 4D and
S6 Table). These data suggest that natural primary DENV-1 infection not only induces the
expression of interferon-induced gene products in a wide range of cell type, but that the physiological consequence this response is profound and widely distributed.

Transcriptional profile overlap between experimental and natural primary
DENV infections
Having identified cell-specific conserved sets of differently expressed genes present in PBMC
subpopulations following experimental and natural primary DENV infection, we assessed the
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Fig 4. Temporal and transcriptional characterization of natural primary DENV-1 infection and identification of conserved gene
signatures. A) Quantification of differential gene expression across all major leukocyte populations following natural primary DENV-1
infection. Subject- and population-specific differentially expressed genes (DEGs) were defined by a Wilcoxon rank-sum test with a Bonferroni
correction relative to the 6-month control sample for each subject. B) Population-restricted frequency of cDEGs from both natural primary
DENV-1 infection subjects. C) Expression of select induced cDEGs within the indicated cell populations across all study time points. D)
Expression of select induced cDEGs within the indicated cell populations across all study time points.
https://doi.org/10.1371/journal.ppat.1009240.g004
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009240 January 29, 2021
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overlap between these two datasets to compare the conserved transcriptional response to
experimental and natural primary DENV infection. In light of the fact that cells obtained 10
days post infection in the experimental primary DENV-1 infection study contained the most
cDEGs relative to baseline–and corresponded to the peak of RNAemia in all subjects—this
time point was selected for comparison against the natural primary infection dataset.
Although the overall number of infection-induced cDEGs identified in cells from natural
primary DENV-1 infection was greater than that observed following experimental primary
DENV-1 infection, the cell population specific frequencies of infection-induced cDEGs in
each population were highly correlated between the two study arms (R2 = 0.6825, p < 0.0001)
(Fig 5A). Furthermore, the infection-induced cDEGs identified following experimental primary DENV-1 were determined to consistently represent a subset of the cDEGs induced in
natural primary DENV-1 infection (Fig 5B and Table 1). Gene ontogeny analysis revealed
that the infection-induced cDEGs that were found in common to experimental and natural
primary DENV infection datasets fell into classic interferon response pathways and negative
regulation of viral replication (Table 2). Those cDEGs which were unique to natural primary
DENV-1 infection corresponded to gene pathways involved in cytokine secretion, antigen processing/presentation, and detection of viruses (Table 2).
In contrast to the high degree of correlation observed in the cell-population specific frequencies of infection-induced cDEGs, infection-suppressed cDEGs were overwhelming
restricted to those cells obtained following natural primary DENV-1 infection (Fig 5C). However, the few infection-suppressed cDEGs observed in cells following experimental primary
DENV-1 infection generally represented a subset of those suppressed following natural primary DENV-1 infection (Fig 5D and Table 3). Infection-suppressed cDEGs overwhelming
represented gene products associated with protein translation/elongation, as well as mitochondrial function and biogenesis (Tables 3 and S6). These data suggest that both natural and
experimental primary DENV-1 infection upregulate a similar acute transcriptional program in
similar cells, but that the greater magnitude of the that response elicited by natural primary
DENV-1 infections has a significantly more profound physiological response on basic cellular
processes, broadly suppressing protein translation and mitochondrial function. Furthermore,
these data indicate that monocytes are uniquely responsive to both experimental and natural
primary DENV infection, most notably in the suppression of gene products associated with
protein translation and metabolic activity (Fig 5E).

Discussion
In this study, we utilized high-throughput single-cell RNA sequencing (scRNAseq) technology
to assess the longitudinal transcriptional profile following both experimental and natural primary DENV-1 infections with single-cell resolution. Core sets of conserved Differentially
Expressed Genes that were induced or suppressed by either natural or experimental primary
DENV-1 were identified, and the overlap between the study groups assessed. The infectioninduced cDEGs associated with experimental primary DENV-1 infection were found to reflect
a subset within the larger gene set associated with natural primary DENV-1 infection, primarily corresponding to gene products associated with a cellular response to systemic inflammation and interferon production. In contrast, infection-suppressed cDEGs were much more
common in cells obtained from natural primary DENV-1 infection than in cells obtained from
experimental primary DENV-1 infection. Infection-suppressed cDEGs primarily corresponded to gene products associated with protein translation/elongation and mitochondrial
function: two cellular processes known to be suppressed by IFN signaling. These results are
consistent with the notion that the immune response elicited by an experimental primary
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Fig 5. Transcriptional profile overlap of experimental and natural primary DENV-1 infection A) Frequency and cell-population
distribution of infection-induced cDEGs identified following experimental or natural primary DENV-1 infection. Experimental primary
DENV-1 infection cDEGs restricted to study day 10. B) Frequency and overlap of infection-induced cDEGs identified following
experimental or natural primary DENV-1 infection C) Frequency and cell-population distribution of infection-suppressed cDEGs
identified following natural primary or experimental DENV-1 infection. Experimental primary DENV-1 infection cDEGs restricted to
study day 10. D) Frequency and overlap of infection-suppressed cDEGs identified following natural or experimental primary DENV-1
infection. F) Schematic representation of the differential gene expression responses observed following either natural or experimental
primary DENV infection.
https://doi.org/10.1371/journal.ppat.1009240.g005
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Table 1. Conserved and unique infection-induced cDEG identified following natural primary DENV-1 infection or experimental primary DENV-1 infection on
study day 10.
Population

Unique: Experimental primary DENV-1

Common: Experimental AND natural primary
DENV-1 infection

Unique: Natural primary DENV-1 infection

Conventional
monocytes

HBB, HES4, NCF1, STAT2, TNFSF13B,
TXNIP, WARS

APOBEC3A, EIF2AK2, EPSTI1, GBP1, IFI35,
IFI44, IFI44L, IFI6, IFITM1, IFITM2, IFITM3,
IRF7, ISG15, ISG20, LAP3, LY6E, MT2A, MX1,
MX2, OAS1, OAS3, OASL, PARP14, PLAC8,
PLSCR1, PSMB9, PSME2, RNF213, RSAD2,
SAMD4A, SERPING1, SIGLEC1, STAT1,
TMEM123, TNFSF10, TRIM22, TYMP, UBE2L6,
VAMP5, XAF1

BST2, CCL2, CCR1, CMPK2, CTSL, CXCL10,
DDX58, DDX60L, DRAP1, FCGR1A, GBP4,
GBP5, GCH1, GIMAP4, HERC5, HLA-A,
HLA-B, HLA-C, HSH2D, IFI16, IFI27, IFIH1,
IFIT1, IFIT2, IFIT3, IL1RN, LGALS3BP,
LGALS9, MAFB, MARCKS, MYL12A, NAPA,
NMI, NT5C3A, OAS2, PARP12, PARP9,
PHF11, PML, PSMA4, RNASE2, SAMD9,
SAMD9L, SCO2, SELL, SMCHD1, SP110,
SPATS2L, TCN2, USP18, XRN1, ZBP1

CD16hi
monocytes

BST2, GBP1, HES4, IFITM1, IFITM3, LAP3,
LY6E, OAS1, PARP14, PLAC8, PSMB9,
PSME2, TMEM123, TNFSF13B, TYMP,
UBE2L6, VAMP5, WARS

APOBEC3A, CXCL10, EIF2AK2, EPSTI1,
HERC5, IFI35, IFI44, IFI44L, IFI6, IFIT2, IRF7,
ISG15, MX1, MX2, NCF1, OAS3, PLSCR1,
RSAD2, SERPING1, TNFSF10, TRIM22, XAF1

CD300E, CDKN1A, DDX58, DDX60L, FFAR2,
GBP4, GLUL, HLA-A, IFI27, IFIH1, IFIT1,
IFIT3, LGALS3BP, LGALS9, MARCKS, OASL,
SAMD9L, SIGLEC1, SPATS2L, TCN2, USP18,
ZBP1

CD4 memory

IFITM2

BST2, EIF2AK2, EPSTI1, IFI44, IFI44L, IFI6,
ADAR, DRAP1, GBP1, HERC5, HLA-A,
IFITM1, ISG15, ISG20, LY6E, MX2, PARP9,
HLA-B, HLA-E, IER2, IFI16, IFI35, IFIT3,
PLSCR1, PSMB9, SP100, STAT1, TRIM22, XAF1 IFITM3, IRF7, LGALS9, MT2A, MX1, OAS1,
OAS3, OASL, PARP10, PARP12, PHF11,
PSME2, RNF213, RSAD2, SAMD9, SAMD9L,
SMCHD1, SP110, TNFSF10, TYMP, UBE2L6,
ZBP1

NK/NKT

IFITM2, LGALS1, PSMB9, PSME2, SHISA5

BST2, EIF2AK2, EPSTI1, IFI35, IFI44L, IFI6,
IFITM1, IFITM3, IRF7, ISG15, ISG20, LY6E,
MX1, MX2, PARP9, PLSCR1, STAT1, TRIM22,
TYMP, UBE2L6, XAF1

ADAR, CD38, DTX3L, GBP1, IFI16, IFI44,
IFIT1, IFIT3, LAG3, LGALS9, MT2A,
NT5C3A, OAS1, OAS2, OAS3, OASL, PARP12,
PRF1, RNF213, RSAD2, S100A11, SAMD9,
SAMD9L, SP100, WARS, ZBP1

CD8 EM

IFITM2

BST2, DRAP1, EIF2AK2, IFI35, IFI44L, IFI6,
IFITM1, IFITM3, IRF7, ISG15, ISG20, LY6E,
MT2A, MX1, MX2, PLSCR1, PSMB9, PSME2,
SP100, STAT1, TRIM22, XAF1

ADAR, CD38, EPSTI1, GBP1, HERC5, IFI16,
IFI44, IFIT1, IFIT3, LAG3, LGALS9, OAS1,
OAS2, OASL, PARP10, PARP9, PRF1, RNF213,
RSAD2, S100A11, SAMD9, SAMD9L, SP110,
TAP1, TYMP, UBE2L6

https://doi.org/10.1371/journal.ppat.1009240.t001

DENV-1 infection represents a tempered version of that generated in response to a natural primary DENV-1 infection, but that the more pronounced inflammation associated with natural
primary DENV-1 infection has a correspondingly distinct impact on basic cellular processes to
induce a multi-layered systemic anti-viral state. These data provide insight into the molecular
level response to primary DENV-1 infection, and how viral pathogenesis correlates with
immune activation and cellular pathophysiology.
Interferon-induced gene products render cells inhospitable to viral replication and propagation through multiple mechanisms. These includes the expression of gene products that
directly degrade viral RNA/DNA, the post-translational inhibition of viral entry and/or budding, post-translation inhibition of protein translation, as well as restriction of key metabolites
and macromolecules required for virus replication and virion assembly [20]. Transcriptionally
repressing the expression of gene products necessary for protein translation/elongation and
mitochondrial function is one of the less specific–though highly effective–methods by which
IFN exposure can limit viral replication [18,20]. This process of broadly inhibiting a function
so central to cellular survival is understandably tightly regulated, and subject to multiple
homeostatic feedback loops. While the data presented herein cannot formally demonstrate a
causal relationship between the expression of IFN-induced gene products and the suppression
of protein translational and cellular metabolism, it does suggests that a tipping point may exist,
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Table 2. Enriched GO terms in overlapping and natural infection only cell populations.
Experimental AND Natural primary DENV-1 infection
GO
term

Description

FE

FDR

Natural primary DENV-1 infection ONLY

Cell type

Rank

GO
term

Description

FE

FDR

Conventional
mono

1

0032020 ISG15-protein conjugation

> 100 3.20E-02 0034344 regulation of type III interferon production

> 100 1.30E-02

Conventional
mono

2

0060700 regulation of ribonuclease
activity

> 100 5.92E-04 0035549 positive regulation of interferon-beta secretion

> 100 2.42E-02

Conventional
mono

3

0016185 synaptic vesicle budding from
presynaptic endocytic zone
membrane

> 100 3.95E-02 0009597 detection of virus

> 100 3.06E-02

Conventional
mono

4

0035455 response to interferon-alpha

> 100 1.15E-08 0035547 regulation of interferon-beta secretion

> 100 3.03E-02

Conventional
mono

5

0060337 type I interferon signaling
pathway

> 100 6.28E-25 0039528 cytoplasmic pattern recognition receptor
signaling pathway in response to virus

> 100 3.00E-02

Conventional
mono

6

0071357 cellular response to type I
interferon

> 100 4.19E-25 0002480 antigen processing and presentation of
exogenous peptide antigen via MHC class I,
TAP-independent

> 100 1.29E-03

Conventional
mono

7

0034340 response to type I interferon

> 100 8.74E-25 0002486 antigen processing and presentation of
endogenous peptide antigen via MHC class I
via ER pathway, TAP-independent

94.78 2.35E-03

Conventional
mono

8

0045071 negative regulation of viral
genome replication

> 100 2.03E-19 0002484 antigen processing and presentation of
endogenous peptide antigen via MHC class I
via ER pathway

94.78 2.30E-03

CD16hi monos

1

0032020 ISG15-protein conjugation

> 100 1.27E-02 0034344 regulation of type III interferon production

> 100 6.83E-03

CD16hi monos

2

0016185 synaptic vesicle budding from
presynaptic endocytic zone
membrane

> 100 1.59E-02 0035549 positive regulation of interferon-beta secretion

> 100 1.11E-02

CD16hi monos

3

0140239 postsynaptic endocytosis

> 100 2.31E-02 0009597 detection of virus

> 100 1.29E-02

CD16hi monos

4

0098884 postsynaptic neurotransmitter
receptor internalization

> 100 2.25E-02 0035547 regulation of interferon-beta secretion

> 100 1.26E-02

CD16hi monos

5

0070142 synaptic vesicle budding

> 100 2.46E-02 0039528 cytoplasmic pattern recognition receptor
signaling pathway in response to virus

> 100 1.23E-02

CD16hi monos

6

0060337 type I interferon signaling
pathway

> 100 3.16E-16 1902741 positive regulation of interferon-alpha
secretion

> 100 2.56E-02

CD16hi monos

7

0071357 cellular response to type I
interferon

> 100 2.81E-16 1902739 regulation of interferon-alpha secretion

> 100 2.51E-02

CD16hi monos

8

0099590 neurotransmitter receptor
internalization

> 100 4.18E-02 0071360 cellular response to exogenous dsRNA

> 100 1.53E-03

Memory CD4

1

0035455 response to interferon-alpha

> 100 4.30E-06 0002519 natural killer cell tolerance induction

> 100 5.10E-03

Memory CD4

2

0035455 response to interferon-beta

> 100 7.09E-08 0042270 protection from natural killer cell mediated
cytotoxicity

> 100 9.10E-03

Memory CD4

3

0060337 type I interferon signaling
pathway

> 100 1.73E-14 0002480 antigen processing and presentation of
exogenous peptide antigen via MHC class I,
TAP-independent

> 100 3.11E-04

Memory CD4

4

0071357 cellular response to type I
interferon

> 100 1.30E-14 0060700 regulation of ribonuclease activity

> 100 3.04E-04

Memory CD4

5

0034340 response to type I interferon

> 100 1.90E-14 0032020 ISG15-protein conjugation

> 100 1.17E-02

Memory CD4

6

0045071 negative regulation of viral
genome replication

> 100 1.24E-08 0002486 antigen processing and presentation of
endogenous peptide antigen via MHC class I
via ER pathway, TAP-independent

> 100 5.99E-04

Memory CD4

7

0048525 negative regulation of viral
process

89.11 3.23E-11 0002484 antigen processing and presentation of
endogenous peptide antigen via MHC class I
via ER pathway

> 100 5.87E-04

Memory CD4

8

1903901 negative regulation of viral life
cycle

81.77 7.16E-08 2001187 positive regulation of CD8-positive, alpha-beta
T cell activation

> 100 1.71E-02
(Continued )
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Table 2. (Continued)
Experimental AND Natural primary DENV-1 infection
Cell type

Rank

NK/NKT

1

GO
term

Description

0016185 synaptic vesicle budding from
presynaptic endocytic zone
membrane

FE

Natural primary DENV-1 infection ONLY

FDR

GO
term

Description

FE

FDR

> 100 1.02E-02 0060700 regulation of ribonuclease activity

> 100 8.34E-07

NK/NKT

2

0140239 postsynaptic endocytosis

> 100 1.28E-02 0032069 regulation of nuclease activity

> 100 1.62E-05

NK/NKT

3

0098884 postsynaptic neurotransmitter
receptor internalization

> 100 1.91E-02 0060337 type I interferon signaling pathway

> 100 1.22E-12

NK/NKT

4

0035455 response to interferon-alpha

> 100 1.87E-02 0071357 cellular response to type I interferon

> 100 9.73E-13

NK/NKT

5

0070142 synaptic vesicle budding

> 100 3.96E-08 0035455 response to interferon-alpha

96.53 2.38E-03

NK/NKT

6

0035456 response to interferon-beta

> 100 2.14E-02 0034340 response to type I interferon

96.53 1.48E-12

NK/NKT

7

0060337 type I interferon signaling
pathway

> 100 8.49E-10 0045071 negative regulation of viral genome replication

87.19 2.11E-09

NK/NKT

8

0071357 cellular response to type I
interferon

> 100 8.20E-21 0060333 interferon-gamma-mediated signaling pathway

75.08 5.36E-09

CD8 EM

1

0016185 synaptic vesicle budding from
presynaptic endocytic zone
membrane

> 100 1.21E-02 0060700 regulation of ribonuclease activity

> 100 1.65E-04

CD8 EM

2

0140239 postsynaptic endocytosis

> 100 1.77E-02 0016185 synaptic vesicle budding from presynaptic
endocytic zone membrane

> 100 1.54E-02

CD8 EM

3

0098884 postsynaptic neurotransmitter
receptor internalization

> 100 1.74E-02 0140239 postsynaptic endocytosis

> 100 2.26E-02

CD8 EM

4

0035455 response to interferon-alpha

> 100 4.36E-08 0098884 postsynaptic neurotransmitter receptor
internalization

> 100 2.22E-02

CD8 EM

5

0070142 synaptic vesicle budding

> 100 1.94E-02 0070142 synaptic vesicle buddin

> 100 2.61E-02

CD8 EM

6

0060337 type I interferon signaling
pathway

> 100 1.06E-22 0035455 response to interferon-alpha

> 100 1.76E-05

CD8 EM

7

0071357 cellular response to type I
interferon

> 100 5.32E-23 0060340 positive regulation of type I interferonmediated signaling pathway

> 100 3.93E-02

CD8 EM

8

0035456 response to interferon-beta

> 100 9.32E-10 0035457 cellular response to interferon-alpha

> 100 3.86E-02

https://doi.org/10.1371/journal.ppat.1009240.t002

Table 3. Conserved and unique infection-suppressed cDEG identified following natural primary DENV-1 infection or experimental primary DENV-1 infection on
study day 10.
Population

Unique: Experimental
primary DENV-1

Common: Experimental AND
natural primary DENV-1 infection

Unique: Natural primary DENV-1 infection

CD16hi monocytes IL1B, AHNAK

RPL10A, RPL3, MT-ND4, MT-CYB

RPL6, RPS3A, EEF1A1, RPS15A, RPL10, RPS13, RPS8, RPS23, RPL34,
RPS4X, RPS27A, RPL8, RPL14, RPS14, RPS7, RPL18A, RPS6, RPL12, RPLP2,
RPL35A, RPL18, RPL11, RPL21, RPL7A, RPL9, RPL5, SLC25A6, RPL32,
RPS24, RPS21, RPL13, RPL30, RPL4, MT-CO3, RPL19, RPL22, RPS16,
RPL26, RPL15, GNB2L1, COTL1, PABPC1, SLC25A5, ACTG1, EEF2,
EEF1B2, NACA, RPLP0, RPL27, RPS25, RPS5, TPT1, RPL23A, RPS3, RPSA,
RPS18, PFDN5, EIF3K, RPL37A, UQCRB, BTF3, RPL29, MT-ND3, RPS4Y1,
RPL23, YBX1, CCNI, RPS17, NAP1L1, EIF3L, RBM3

Conventional
monocytes

RPS3A, RPL4, EEF2, RPL6, RPL5,
EIF3L, RPL3

TPT1, RPS28, EEF1A1, RPS13, RPLP1, RPL8, RPL18, RPS7, RPS14, RPL34,
RPS24, RPL35A, RPS15A, MT-ND3, MT-CO3, RPS8, RPS4X, RPL11, RPL10,
RPL19, RPL9, NACA, RPL22, RPL26, RPL37, RPS23, RPL15, RPL7A, RPL32,
RPL18A, BTF3, RPL30, RPLP2, RPS16, RPS27A, RPS6, RPLP0, RPL29,
COX4I1, PABPC1, CSTA, COTL1, SLC25A6, RPL27, RPL13, RPL10A, RPS5,
EEF1B2, RPL21, AP1S2, RPS3, GSTP1, RPS18, PCBP2, RPL7, GNB2L1,
SLC25A5, RPS4Y1, ALDH2, EIF3F, RBM3, FCGRT, EIF3E, EIF3H, CRTAP

IL1B, CXCL8, EIF4B

https://doi.org/10.1371/journal.ppat.1009240.t003
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where the magnitude of the interferon-induced transcriptional response reaches a threshold,
whereupon a broader range of cellular factors are significantly impacted causing a qualitative
change in transcriptional response to infection.
The observation that both the induction of IFN-responsive gene products as well as the suppression of genes associated with protein translation and mitochondrial function was most
dramatically and consistently observed in conventional and CD16hi monocytes may help
explain certain discrepancies in the literature regarding DENV cellular tropism. Historically,
monocytes, macrophages, and dendritic cells have been cited as the primary circulating cellular reservoir of DENV [21,22]. However, this assertion was primarily based primarily on in
vitro infection experiments, where the impact of systemic inflammation and interferon signaling may not impact cellular permissiveness to infection. More recent studies utilizing flow
cytometry, RT-PCR, and scRNAseq analysis have suggested that B cells are the principal circulating natural reservoir of DENV [23–28]. Our observation that monocytes appear to respond
more dramatically to DENV-elicited systemic inflammation than B cells suggests that while
monocytes are more permissive to infection in vitro, they become a much less attractive target
of infection and replication in vivo. However, while a profound transcriptional response to
both experimental and natural primary DENV-1 infection was observed in this analysis, it is
notable that we were unable to detect any cell-associated viral RNA from any subject or sample. This despite the fact that we have previously demonstrated that the scRNAseq platform
used in this analysis is capable of identifying and quantifying cells harboring DENV genomic
RNA [28]. These previous studies utilized either in vitro infected cells or PBMC from individuals experiencing a secondary DENV infection, which has been shown to result in a higher cellassociated DENV burden [23]. Therefore, the lower viral burden associated with primary
DENV infection may not provide enough of a signal to be reliably captured using this analysis
platform. It is also acknowledged here that DENV has demonstrated tropism for tissues such
as skin, spleen, lymph nodes, liver and bone marrow, and hence, tissue-resident infected cells
may be important drivers of systemic inflammation [29–31]. Consequently, the relative abundance of virally infected cells–and their role in driving the inflammatory profile described
herein–remains unresolved.
Although the data presented herein represents an extremely high-resolution transcriptional
assessment of both natural and experimental primary DENV-1 infection, several limitations of
the study must be acknowledged. Firstly, the relatively small numbers of subjects analyzed in
both arms of the study limits the power of the analysis. Secondly, the significant age and background differences between the subjects are potential confounders for the analysis. In addition
to viral genetic differences, the route and method of virus inoculation differs significantly
between natural and experimental primary DENV-1 infection (mosquito bite versus subcutaneous needle). The impact of these variables on the immunological profile described here can
only be addressed with further focused studies guided by the data presented here.
Taken together, the data presented in this study demonstrates that the immunological
response elicited by the administration of an attenuated DENV in an experimental setting
involves many of the same molecular pathways in the same cells as wild-type, naturallyacquired primary DENV. This includes the activation and expansion of lymphocyte populations (T/NK/NKT cells and plasmablasts), as well as predictable perturbation of the transcriptional profile in all major leukocyte subsets. However, natural infection results in a more
pronounced pattern of inflammatory gene upregulation accompanied by marked suppression
of gene products associated with protein translation and mitochondrial function, particularly
among monocyte populations. This study highlights the pivotal role that monocytes play in
responding to acute DENV infection, potentially offering a framework to develop more accurate and rapid diagnostic metrics in the future.
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Materials and methods
Ethics statement
The Dengue Human Challenge Model and associated analysis was approved by the State University of New York Upstate Medical University (SUNY-UMU) and the Department of
Defense’s Human Right Protection Organization (Identification: WRAIR #2237). The Natural
primary DENV infection sample collection protocol and associated analysis was approved by
the Institutional Review Boards of the Thai Ministry of Public Health, the Office of the U.S.
Army Surgeon General, and the University of Massachusetts Medical School (Identification:
WRAIR #1620).

Dengue human challenge model
Peripheral blood mononuclear cells (PBMC) and plasma for this study were obtained from the
previously described phase 1 open label, Dengue Virus-1 Live Virus Human Challenge
(DENV-1-LVHC) study performed at the State University of New York, Upstate Medical University in Syracuse, NY [12]. The study was approved by the State University of New York
Upstate Medical University (SUNY-UMU) and the Department of Defense’s Human Right
Protection Organization (HRPO). ClinicalTrials.gov identifier for this trial is NCT02372175.
All subjects included in this study received 3.25 x 103 PFU of the 45AZ5 DENV-1 challenge
strain virus following pre-screening to ensure an absence of preexisting DENV immunity. The
45AZ5 DENV-1 challenge strain used in this study was generated by serial passage of the
parental Nauru/West Pac/1974 DENV-1 isolate through diploid fetal rhesus lung cell line
(FRhL) in the presence of 5-azacytidine, followed by plaque cloning and secondary amplification in FRhL cells [15,16]. Flavivirus antibody screening, dengue IgM and IgG ELISA, microneutralization assay and quantitative reverse-transcriptase polymerase chain reaction
(RT-PCR) were performed at the Viral Diseases Branch, Walter Reed Army Institute of
Research (WRAIR) in Silver Spring, Maryland using previously published techniques [32–35].

Natural primary DENV infection sample collection
PBMC and plasma were isolated from whole blood specimens obtained from children enrolled
in a hospital-based acute febrile illness study in Bangkok, Thailand, the design of which has
been previously described [36,37]. In brief, the study enrolled children who presented to the
hospital with acute febrile illness. Blood samples were obtained daily during illness and at early
and late convalescent time points; the term ‘fever day’ is used to report acute illness time points
relative to Day 0, defined as the day of defervescence. The infecting virus type (DENV-1-4)
was determined by RT-PCR and/or virus isolation as previously described [38], and serology
(EIA and HAI assays) was used to distinguish primary and secondary DENV infections [39].
IgM/IgG EIA values were calculated using a standard binding index assay and the following
formula: EIA units = ((OD (average test sample)–OD (average negative control)) /(OD (average weak positive control)–OD (average negative control)) � 100). Written informed consent
was obtained from each subject and/or his/her parent or guardian. The study protocol was
approved by the Institutional Review Boards of the Thai Ministry of Public Health, the Office
of the U.S. Army Surgeon General, and the University of Massachusetts Medical School.
PBMC and plasma samples were cryopreserved for later analysis.

Flow cytometry
Cryopreserved PBMC were thawed and placed in RPMI 1640 medium supplemented with
10% heat-inactivated fetal bovine serum, L-glutamine, penicillin, and streptomycin prior to
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analysis. Cell viability was assessed using CTL-LDC Dye (Cellular Technology Limited [CTL],
Shaker Heights, OH) and a CTL-ImmunoSpot S6 Ultimate-V Analyzer (CTL). Surface staining for flow cytometry analysis was performed in PBS supplemented with 2% FBS at room
temperature. Aqua Live/Dead or Violet Live/Dead dye (ThermoFisher) was used to exclude
dead cells in all experiments. Antibodies and dilutions used for flow cytometry analysis are
listed in S7 Table. Flow cytometry analysis was performed on a custom-order BD LSRFortessa
instrument, and data analyzed using FlowJo v10.2 software (Treestar).

Single-cell RNA sequencing library generation
Thawed PBMC suspensions were prepared for single-cell RNA sequencing using the Chromium Single-Cell 50 Reagent version 2 kit and Chromium Single-Cell Controller (10x Genomics, CA)[40]. 2000–8000 cells per reaction suspended at a density of 50–500 cells/μL in PBS
plus 0.5% FBS were loaded for gel bead-in-emulsion (GEM) generation and barcoding.
Reverse transcription, RT-cleanup, and cDNA amplification were performed to isolate and
amplify cDNA for downstream 50 gene or enriched V(D)J library construction according to
the manufacturer’s protocol. Libraries were constructed using the Chromium Single-Cell 50
reagent kit, V(D)J Human B Cell Enrichment Kit, 30 /50 Library Construction Kit, and i7 Multiplex Kit (10x Genomics, CA) according to the manufacturer’s protocol.

Sequencing
scRNAseq 50 gene expression libraries and BCR V(D)J enriched libraries were sequenced on an
Illumina NovaSeq 6000 instrument using the S2, or S4 reagent kits (300 cycles). Libraries were
balanced to allow for ~150,000 reads/cell for 50 gene expression libraries. Sequencing parameters were set for 150 cycles for Read1, 8 cycles for Index1, and 150 cycles for Read2. Prior to
sequencing, library quality and concentration were assessed using an Agilent 4200 TapeStation
with High Sensitivity D5000 ScreenTape Assay and Qubit Fluorometer (Thermo Fisher Scientific) with dsDNA BR assay kit according to the manufacturer’s recommendations.

5’ gene expression analysis/visualization
50 gene expression alignment from all PBMC samples was performed using the 10x Genomics
Cell Ranger pipeline [40]. Sample demultiplexing, alignment, barcode/UMI filtering, and
duplicate compression was performed using the Cell Ranger software package (10x Genomics,
CA, v2.1.0) and bcl2fastq2 (Illumina, CA, v2.20) according to the manufacturer’s recommendations, using the default settings and mkfastq/count commands, respectively. Transcript
alignment was performed against a human reference library generated using the Cell Ranger
mkref command, the Ensembl GRCh38 v87 top-level genome FASTA, and the corresponding
Ensembl v87 gene GTF.
Multi-sample integration, data normalization, dimensional reduction, visualization, and
differential gene expression were performed using the R package Seurat (v3.1.4) [41,42]. All
datasets were filtered to only contain cells with between 200–6,000 unique features and <10%
mitochondrial RNA content. To eliminate erythrocyte contamination, datasets were additionally filtered to contain cells with less than a 5% erythrocytic gene signature (defined as HBA1,
HBA2, HBB). Data were scaled, normalized, and transformed prior to multi-sample integration using the negative binomial regression model of the Seurat SCTransform() function [43].
SelectIntegrationFeatures() and PrepSCTIntegration() functions were used to identify conserved features for dataset integration, and final dataset anchoring/integration were performed
using FindIntegrationAnchors() and IntegrateData() functions, with the day 0 experimental
DENV-1 infection samples and day 180 natural primary DENV-1 infection samples used as
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reference datasets. PCA was performed using variable genes defined by SCTransform() additionally filtered to remove TCR V/D/J or BCR κ/λ gene segments. The first 33 resultant PCs
were used to perform a UMAP dimensional reduction of the dataset (RunUMAP()) and to
construct a shared nearest neighbor graph (SNN; FindNeighbors()). This SNN was used to
cluster the dataset (FindClusters()) with default parameters and resolution set to 0.4.
Following dataset integration and dimensional reduction/clustering, gene expression data
was loge(UMI+1) transformed and scaled by a factor of 10,000 using the NormalizeData()
function. This normalized gene expression data was used to determine cellular cluster identity
by utilizing the Seurat application of a Wilcoxon rank-sum test (FindAllMarkers()), and comparing the resulting differential expression data to known cell-linage specific gene sets. Differential gene expression analysis between study time points was performed using normalized
gene expression data and the Wilcoxon rank-sum test with implementation in the FindMarkers() function, with a loge fold chain threshold of 0.5 and min.pct of 0.25. Bonferroni correction was used to control for Fall Discovery Rate (FDR), with a corrected p value of < 0.05
considered significant.

Statistical analysis
Differential gene expression analysis of scRNAseq data was performed using normalized gene
expression counts and the Wilcoxon rank-sum test in the Seurat FindMarkers() function
[41,42]. A loge fold chain threshold for gene expression changes of 0.5 and min.pct of 0.25 was
used for all comparisons, and a Bonferroni correction was used to control for Fall Discovery
Rate (FDR). A corrected p value of < 0.05 considered significant in conjunction with the additional filters above. All other statistical analysis was performed using GraphPad Prism 8 Software (GraphPad Software, La Jolla, CA). A P-value < 0.05 was considered significant.

Supporting information
S1 Fig. Schematic representation of the analysis scheme utilized in this study.
(TIF)
S2 Fig. Flow cytometry gating scheme for monocyte, DC, and B cell phenotyping from
experimental primary DENV-1 infection samples.
(TIF)
S3 Fig. Flow cytometry gating scheme for T and NK cell phenotyping for experimental primary DENV-1 infection samples.
(TIF)
S4 Fig. Experimental primary DENV-1 associated lymphocyte expansion, A) Expansion of
transcriptionally defined plasmablasts as a fraction of all B cells in response to experimental
primary DENV-1 infection B) Expansion of transcriptionally defined activated T cells as a
fraction of all T cells in response to experimental primary DENV-1 infection.
(TIF)
S5 Fig. Plasmablast expansion following experimental primary DENV-1 infection. Cells
are gated on CD3-CD56-CD19+ viable lymphocytes.
(TIF)
S6 Fig. CD4+ T cell and CD8+ T cell activation following experimental primary DENV-1
infection. T cells defined as viable CD3+ CD56- lymphocytes.
(TIF)
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S7 Fig. Correlation between population frequencies as defined by scRNAseq or flow
cytometry in all experimental primary DENV-1 infection samples. Population frequency
defined as percent of all cells.
(TIF)
S8 Fig. Number of differentially express genes in the indicated populations relative to baseline. Experimental primary DENV-1 samples are from study day 10. Natural primary DENV1 infection samples are from acute 1/acute 2 time points �� p <0.01, ��� p <0.001, unpaired
two-tailed t test.
(TIF)
S1 Table. Natural primary DENV-1 infection subject information.
(DOCX)
S2 Table. Sample sequencing metrics.
(DOCX)
S3 Table. Sample/population frequency: T cell populations.
(DOCX)
S4 Table. Sample/population frequency: B cells and myeloid linage cells.
(DOCX)
S5 Table. Conserved differentially expressed genes: day 10 Experimental primary DENV-1
infection.
(DOCX)
S6 Table. Core differentially expressed genes: natural primary DENV-1 infection.
(DOCX)
S7 Table. Antibodies used for flow cytometry.
(DOCX)
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